How long does ACE-031 (ACVR2B-Fc) take to work?
In the first week of ACE-031 (ACVR2B-Fc), early reports describe muscle volume increase within days. Around week 4, trial endpoint for some Phase 1 cohorts. Safety signals emerged here. By week 8, no long-cycle human safety data, Acceleron halted further dosing. Response varies between people, this is the commonly reported pattern, not a guarantee.
Week by week
- Week 1: Early reports describe muscle volume increase within days.
- Week 4: Trial endpoint for some Phase 1 cohorts. Safety signals emerged here.
- Week 8: No long-cycle human safety data, Acceleron halted further dosing.
References
- ACE-031 (soluble activin receptor IIB) increases muscle mass, Phase 1 in postmenopausal women — Attie KM et al., Muscle Nerve, 2013
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial — Campbell C, McMillan HJ, Mah JK, et al., Muscle & Nerve, 2017
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ACE-031 (ACVR2B-Fc)
Last updated 2026-06-06.